Durvalumab vs Methocarbamol

## Durvalumab vs Methocarbamol: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Methocarbamol**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Methocarbamol — N/A.

## Chemical Properties

**Type**: Durvalumab — Antibody; Methocarbamol — Small molecule.